February 1, 2022

Interview with Dr. Pernessa Seele

Interview with Dr. Pernessa Seele

About This Episode

BrainStorm looks at the future through a societal lens as the US population transitions to minority majority.  Dr. Pernessa Seele, founder and CEO of The Balm in Gilead and longtime public health advocate, talks about the public health implications of this shift. Host, Meryl Comer, and Dr. “P” discuss the burden, impact and reality of stigma. With three decades of training and services to prevent disease and improve the health status of people of African descent, she is well aware of the hurdles to overcome and undo the stigma. 

BrainStorm Feed

100

2025 Year in Review and Predictions for 2026 with George Vradenburg

George Vradenburg, Chairman and Founder of UsAgainstAlzheimer's, sits down with host Meryl Comer for a comprehensive look at the state of Alzheimer's research, advocacy, and care in 2025.
LISTEN NOW
99

The Future of Alzheimer's Trials: AI, Biomarkers, and Remote Research – John Dwyer, CEO of The Global Alzheimer’s Platform (part 2)

In part 2 John Dwyer, CEO of the Global Alzheimer's Platform (GAP), and BrainStorm host Meryl Comer discuss transforming Alzheimer's research and clinical trials.
LISTEN NOW
98

The Future of Alzheimer's Trials: Bringing Cutting-Edge Research to Every Community - John Dwyer, CEO of The Global Alzheimer's Platform

John Dwyer, CEO of the Global Alzheimer's Platform (GAP), highlights GAP's innovations in improving the participant experience through streamlining visits, personalized feedback, and bringing mobile trials directly to small communities.
LISTEN NOW